Companies
InVitria
the global leader in chemically-defined animal-origin-free recombinant proteins for biologics manufacturing, with an ISO 9001:2015-certified cGMP facility; its rice-based ExpressTec platform is the first plant-based recombinant expression system to support an FDA-, EMA-, and PMDA-approved injectable biologic;…
- Country
- United States
Exbumin excipient in Merck ERVEBO Ebola vaccine since 2019 (250,000+ injections); Optibumin 25 launched Apr 29, 2025
us
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | InVitria has received non-dilutive NIH/NIAID SBIR grants (e.g., $725,000 in 2009 and $1,500,000 in 2012) rather than priced venture rounds. | biobase.whitefordresearch.com |
| Funding | No funding disclosed. medium confidence | prospeo.io |
| Certification | ISO 9001:2015 certified for the manufacture of purified and partially purified products of recombinant proteins extracted from transgenic plants. | invitria.com |
| Production site | 2718 Industrial Drive, Junction City, Kansas 66441, USA. | invitria.com |
| Production site | Fulfillment facility in Rotterdam, the Netherlands (opened October 2024). | invitria.com |
| Revenue | Estimates vary significantly across sources, ranging from $4.2 million to $53 million annually. medium confidence | invitria.com · prospeo.io · datanyze.com |
Independent sources: biobase.whitefordresearch.com · datanyze.com · prospeo.io
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant human serum albumin (rHSA) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.